British Journal of Clinical Pharmacology · 1979 · 59 citations · 7 references
MedicineCardiologyPharmacologyClinical PharmacologyExperimental PharmacologyPharmacodynamicsCardiovascular DiseaseCardiovascular PharmacodynamicsCardiovascular PharmacologyHemodynamic PharmacologyArterial Blood Pressure MeasurementBeta-adrenergic Receptor PharmacodynamicsCardiac OutputCardiac Output AugmentationCardiovascular Drug PharmacologyHeart RateHemodynamic Drug EffectsMyocardial Contractility Modulation
1 Prenalterol, (S-(-)-1-(4 hydroxyphenoxy)-3-isopropylaminopropanol-2 hydrochloride) a cardio-selective beta-adrenergic receptor agonist, was infused intravenously into six normal male volunteers to determine the cardiovascular effects of this drug. 2 On different occasions, each volunteer received a placebo infusion, an infusion of 0.5 mg prenalterol and an infusion of 1 mg prenalterol. Cardiac output (impedance cardiography), arterial pressure (sphygmomanometry), heart rate and ECG were measured throughout. 3 Prenalterol produced a statistically significant increase in cardiac output and at the end of the infusion this increase was 24% with 0.5 mg and 29% with 1 mg, mainly due to an increase in stroke volume (18% and 17%) with a lesser change in heart rate (+2 and +7 beats/min). Pulse pressure increased but mean arterial pressure showed little change. Peripheral resistance fell by 18% and 20%. As indicated by systolic time indices myocardial contractility increased. 4 Prenalterol at plasma concentrations in excess of 20 nmol l-1 produced significant inotropic effects but did not markedly increase heart rate at concentrations of 60 nmol l-1.
7
The Minnesota impedance cardiograph- theory and applications.
W. G. Kubicek, J Kottke, Marcos U. Ramos et al. · PubMed · 1974 · 401 citations
CLINICAL CARDIOVASCULAR PHARMACOLOGY OF DOBUTAMINE A SELECTIVE INOTROPIC CATECHOLAMINE
D. E. Jewitt, Andrew R.J. Mitchell, John Birkhead et al. · The Lancet · 1974 · 123 citations
Medicine, Cardiology, Pharmacology +10